Nova Biomedical Advances Integrated Cell Line Development Workflows: NanoCellect products are now part of Nova Biomedical
This expands Nova Biomedical's capabilities in cell line development and strengthens its ability to support biopharmaceutical workflows from early development through manufacturing. NanoCellect® WOLF G2® cell sorting platform introduces gentle, microfluidic-based cell selection and isolation, complementing Nova Biomedical's existing Solentim portfolio for clone generation, verification, and growth analysis. Together, these technologies enable a more integrated approach to cell line development—linking cell selection, single-cell isolation, and high-confidence clone verification.
- ▪This expands Nova Biomedical's capabilities in cell line development and strengthens its ability to support biopharmaceutical workflows from early development through manufacturing.
- ▪NanoCellect® WOLF G2® cell sorting platform introduces gentle, microfluidic-based cell selection and isolation, complementing Nova Biomedical's existing Solentim portfolio for clone generation, verification, and growth analysis.
- ▪Together, these technologies enable a more integrated approach to cell line development—linking cell selection, single-cell isolation, and high-confidence clone verification.
2 outlets in our directory ran this story. All of the coverage we found sits in one bucket: centre. That one-sidedness is itself worth noticing.
PR Newswire: files mainly under climate. We currently carry 21 of its stories.
Opening excerpt (first ~120 words) tap to expand
Nova Biomedical Advances Integrated Cell Line Development Workflows: NanoCellect products are now part of Nova Biomedical News provided by Nova Biomedical Jul 24, 2026, 09:46 ET Share this article Share toX Share this article Share toX WALTHAM, Mass., July 24, 2026 /PRNewswire/ -- Nova Biomedical today announced a transaction involving certain assets of NanoCellect, a provider of microfluidic cell sorting technology. This expands Nova Biomedical's capabilities in cell line development and strengthens its ability to support biopharmaceutical workflows from early development through manufacturing.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at PR Newswire:.
Discussion
0 commentsMore from PR Newswire:
